Unituxin Approved for Deadly Pediatric Cancer

March 10, 2015 2:51 PM

4 0

TUESDAY, March 10, 2015 (HealthDay News) -- Unituxin (dinutuximab) has been approved by the U.S. Food and Drug Administration to treat children with high-risk neuroblastoma, a rare cancer that most often affects children aged five and under.

Children with the cancer, which forms from immature nerve cells, have only a 40 percent to 50 percent chance of survival despite aggressive treatment, the FDA said Tuesday in a news release. It occurs in about one of every 100,000 children, slightly more often in boys. Some 650 cases are diagnosed a...

Read more

To category page

Loading...